279 related articles for article (PubMed ID: 30470609)
1. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.
Mole SE; Anderson G; Band HA; Berkovic SF; Cooper JD; Kleine Holthaus SM; McKay TR; Medina DL; Rahim AA; Schulz A; Smith AJ
Lancet Neurol; 2019 Jan; 18(1):107-116. PubMed ID: 30470609
[TBL] [Abstract][Full Text] [Related]
2. Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).
Sands MS
J Child Neurol; 2013 Sep; 28(9):1151-8. PubMed ID: 24014510
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
Hawkins-Salsbury JA; Cooper JD; Sands MS
Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
[TBL] [Abstract][Full Text] [Related]
4. Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis.
Cooper JD
Curr Opin Neurol; 2003 Apr; 16(2):121-8. PubMed ID: 12644737
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
[TBL] [Abstract][Full Text] [Related]
6. Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses.
Donsante A; Boulis NM
Expert Opin Biol Ther; 2018 Jul; 18(7):755-764. PubMed ID: 29936867
[TBL] [Abstract][Full Text] [Related]
7. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
Lewis G; Morrill AM; Conway-Allen SL; Kim B
J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
[TBL] [Abstract][Full Text] [Related]
8. Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis.
Wong AM; Rahim AA; Waddington SN; Cooper JD
Biochem Soc Trans; 2010 Dec; 38(6):1484-8. PubMed ID: 21118112
[TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.
Kohlschütter A; Schulz A; Bartsch U; Storch S
CNS Drugs; 2019 Apr; 33(4):315-325. PubMed ID: 30877620
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological approaches to tackle NCLs.
Kauss V; Dambrova M; Medina DL
Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165553. PubMed ID: 31521819
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lysosomal storage disorders: focus on the neuronal ceroid-lipofuscinoses.
Pierret C; Morrison JA; Kirk MD
Acta Neurobiol Exp (Wars); 2008; 68(3):429-42. PubMed ID: 18668166
[TBL] [Abstract][Full Text] [Related]
12. Experimental gene therapies for the NCLs.
Liu W; Kleine-Holthaus SM; Herranz-Martin S; Aristorena M; Mole SE; Smith AJ; Ali RR; Rahim AA
Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165772. PubMed ID: 32220628
[TBL] [Abstract][Full Text] [Related]
13. The contribution of multicellular model organisms to neuronal ceroid lipofuscinosis research.
Huber RJ; Hughes SM; Liu W; Morgan A; Tuxworth RI; Russell C
Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165614. PubMed ID: 31783156
[TBL] [Abstract][Full Text] [Related]
14. Future perspectives: What lies ahead for Neuronal Ceroid Lipofuscinosis research?
Cooper JD; Mole SE
Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165681. PubMed ID: 31926264
[TBL] [Abstract][Full Text] [Related]
15. Use of model organisms for the study of neuronal ceroid lipofuscinosis.
Bond M; Holthaus SM; Tammen I; Tear G; Russell C
Biochim Biophys Acta; 2013 Nov; 1832(11):1842-65. PubMed ID: 23338040
[TBL] [Abstract][Full Text] [Related]
16. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses.
Warrier V; Vieira M; Mole SE
Biochim Biophys Acta; 2013 Nov; 1832(11):1827-30. PubMed ID: 23542453
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses.
Kleine Holthaus SM; Smith AJ; Mole SE; Ali RR
Adv Exp Med Biol; 2018; 1074():91-99. PubMed ID: 29721932
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis.
Sondhi D; Hackett NR; Apblett RL; Kaminsky SM; Pergolizzi RG; Crystal RG
Arch Neurol; 2001 Nov; 58(11):1793-8. PubMed ID: 11708986
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic perspectives in the neuronal ceroid lipofuscinoses.
Kmoch S; Stránecký V; Emes RD; Mitchison HM
Biochim Biophys Acta; 2013 Nov; 1832(11):1831-41. PubMed ID: 23274885
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic landscape for Batten disease: current treatments and future prospects.
Johnson TB; Cain JT; White KA; Ramirez-Montealegre D; Pearce DA; Weimer JM
Nat Rev Neurol; 2019 Mar; 15(3):161-178. PubMed ID: 30783219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
